Editas Medicine annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Editas Medicine Revenue Growth & History (EDIT)
Editas Medicine reported $40.5M in revenue for fiscal 2025, an increase of 25.39% from the previous fiscal year.
View full Editas Medicine company overviewEditas Medicine annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $40.5M | $8.2M | +25.39% |
| 2024 | 2024-12-31 | $32.3M | −$45.8M | −58.64% |
| 2023 | 2023-12-31 | $78.1M | $58.4M | +296.32% |
| 2022 | 2022-12-31 | $19.7M | −$5.8M | −22.83% |
| 2021 | 2021-12-31 | $25.5M | −$65.2M | −71.85% |
| 2020 | 2020-12-31 | $90.7M | $70.2M | +341.93% |
| 2019 | 2019-12-31 | $20.5M | −$11.4M | −35.71% |
| 2018 | 2018-12-31 | $31.9M | $18.2M | +132.64% |
| 2017 | 2017-12-31 | $13.7M | $7.7M | +126.80% |
| 2016 | 2016-12-31 | $6.1M | $4.4M | +271.58% |
| 2015 | 2015-12-31 | $1.6M | — | — |
Editas Medicine quarterly revenue
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.9M | $8.3M | +232.31% |
| Q1 2026 | 2026-03-31 | $2.8M | −$1.8M | −39.22% |
| Q4 2025 | 2025-12-31 | $24.7M | −$5.9M | −19.16% |
| Q3 2025 | 2025-09-30 | $7.5M | $7.5M | +12265.57% |
| Q2 2025 | 2025-06-30 | $3.6M | $3.1M | +597.47% |
| Q1 2025 | 2025-03-31 | $4.7M | $3.5M | +310.40% |
| Q4 2024 | 2024-12-31 | $30.6M | −$29.4M | −49.03% |
| Q3 2024 | 2024-09-30 | $61,000 | −$5.3M | −98.86% |
| Q2 2024 | 2024-06-30 | $513,000 | −$2.4M | −82.23% |
| Q1 2024 | 2024-03-31 | $1.1M | −$8.7M | −88.48% |
| Q4 2023 | 2023-12-31 | $60.0M | $53.5M | +818.60% |
| Q3 2023 | 2023-09-30 | $5.3M | $5.3M | +12604.76% |
| Q2 2023 | 2023-06-30 | $2.9M | −$3.5M | −54.62% |
| Q1 2023 | 2023-03-31 | $9.9M | $3.1M | +45.49% |
| Q4 2022 | 2022-12-31 | $6.5M | −$5.9M | −47.57% |
| Q3 2022 | 2022-09-30 | $42,000 | −$6.2M | −99.32% |
| Q2 2022 | 2022-06-30 | $6.4M | $6.0M | +1578.63% |
| Q1 2022 | 2022-03-31 | $6.8M | $272,000 | +4.19% |
| Q4 2021 | 2021-12-31 | $12.5M | $1.1M | +9.20% |
| Q3 2021 | 2021-09-30 | $6.2M | −$56.6M | −90.14% |
| Q2 2021 | 2021-06-30 | $379,000 | −$10.4M | −96.47% |
| Q1 2021 | 2021-03-31 | $6.5M | $776,000 | +13.56% |
| Q4 2020 | 2020-12-31 | $11.4M | −$865,000 | −7.04% |
| Q3 2020 | 2020-09-30 | $62.8M | $59.0M | +1533.08% |
| Q2 2020 | 2020-06-30 | $10.7M | $8.4M | +361.33% |
| Q1 2020 | 2020-03-31 | $5.7M | $3.7M | +176.61% |
| Q4 2019 | 2019-12-31 | $12.3M | $6.2M | +100.75% |
| Q3 2019 | 2019-09-30 | $3.8M | −$10.7M | −73.50% |
| Q2 2019 | 2019-06-30 | $2.3M | −$5.0M | −68.39% |
| Q1 2019 | 2019-03-31 | $2.1M | −$1.9M | −47.31% |
| Q4 2018 | 2018-12-31 | $6.1M | $2.5M | +66.87% |
| Q3 2018 | 2018-09-30 | $14.5M | $8.2M | +131.12% |
| Q2 2018 | 2018-06-30 | $7.4M | $4.3M | +138.04% |
| Q1 2018 | 2018-03-31 | $3.9M | $3.2M | +475.81% |
| Q4 2017 | 2017-12-31 | $3.7M | $2.8M | +308.35% |
| Q3 2017 | 2017-09-30 | $6.3M | $5.3M | +553.01% |
| Q2 2017 | 2017-06-30 | $3.1M | −$291,000 | −8.59% |
| Q1 2017 | 2017-03-31 | $682,000 | −$123,000 | −15.28% |
| Q4 2016 | 2016-12-31 | $898,000 | $106,000 | +13.38% |
| Q3 2016 | 2016-09-30 | $962,000 | $292,000 | +43.58% |
| Q2 2016 | 2016-06-30 | $3.4M | $3.2M | +1928.74% |
| Q1 2016 | 2016-03-31 | $805,000 | — | — |
| Q4 2015 | 2015-12-31 | $792,000 | — | — |
| Q3 2015 | 2015-09-30 | $670,000 | — | — |
| Q2 2015 | 2015-06-30 | $167,000 | — | — |
Editas Medicine revenue growth trends
Over the last five reported fiscal years, revenue declined from $90.7M to $40.5M, a compound annual decline of 14.89%. Editas Medicine's latest reported quarter, Q2 2026, generated $11.9M in revenue, an increase of 232.31% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Editas Medicine source filings ↗